Clinical Trials
22 trialsNCT07591090 2026-05-15
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Akeso
Phase 2 Not yet recruiting
NCT07497386 2026-05-11
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT06172127 2026-04-29
DEMETHER
MedSIR
Phase 2 Active not recruiting
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT07130383 2025-11-18
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2 Recruiting
NCT06198751 2025-08-19
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT06199895 2025-06-03
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT06452706 2024-11-19
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06685796 2024-11-13
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2 Recruiting
NCT05911958 2024-11-04
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05621434 2022-11-18
A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer
Fujian Medical University
Phase 2 Unknown
NCT02897050 2022-04-20
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Suspended
NCT03139851 2021-09-10
CHEMOIMMUNE
Centre Leon Berard
Phase 2 Completed
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT03203616 2018-11-29
KIARA
Jules Bordet Institute
Phase 2 Withdrawn
NCT02953184 2017-12-29
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Phase 2 Unknown
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed
NCT01428414 2012-08-23
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Fudan University
Phase 2 Unknown
NCT00955890 2012-02-28
cardioprotec
Fudan University
Phase 2 Terminated